Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance

被引:18
|
作者
Su, Chinh Tran-To [1 ]
Kwoh, Chee-Keong [2 ]
Verma, Chandra Shekhar [1 ]
Gan, Samuel Ken-En [1 ,3 ]
机构
[1] ASTAR, Bioinformat Inst, Singapore 138671, Singapore
[2] Nanyang Technol Univ, Sch Comp Sci & Engn, Singapore 639798, Singapore
[3] ASTAR, P53 Lab, Singapore 138648, Singapore
来源
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS | 2018年 / 36卷 / 16期
关键词
full length HIV-1 Gag structure; p6; subunit; allostery; non-cleavage site mutation; drug resistance; VIRUS TYPE-1 GAG; AMINO-ACID SUBSTITUTIONS; STRUCTURAL BASIS; DOMAIN; FITNESS; CONFORMATION; DIMERIZATION; REPLICATION; INHIBITORS; MOLECULES;
D O I
10.1080/07391102.2017.1417160
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV polyprotein Gag is increasingly found to contribute to protease inhibitor resistance. Despite its role in viral maturation and in developing drug resistance, there remain gaps in the knowledge of the role of certain Gag subunits (e.g. p6), and that of non-cleavage mutations in drug resistance. As p6 is flexible, it poses a problem for structural experiments, and is hence often omitted in experimental Gag structural studies. Nonetheless, as p6 is an indispensable component for viral assembly and maturation, we have modeled the full length Gag structure based on several experimentally determined constraints and studied its structural dynamics. Our findings suggest that p6 can mechanistically modulate Gag conformations. In addition, the full length Gag model reveals that allosteric communication between the non-cleavage site mutations and the first Gag cleavage site could possibly result in protease drug resistance, particularly in the absence of mutations in Gag cleavage sites. Our study provides a mechanistic understanding to the structural dynamics of HIV-1 Gag, and also proposes p6 as a possible drug target in anti-HIV therapy.
引用
收藏
页码:4366 / 4377
页数:12
相关论文
共 9 条
  • [1] HIV-1 Gag cleavage site mutations and non-cleavage site mutations are closely related in viral fitness recovery process
    Myint, L
    Matsuda, M
    Matsuda, Z
    Yokomaku, Y
    Chiba, T
    Okano, A
    Yamada, K
    Sugiura, W
    ANTIVIRAL THERAPY, 2002, 7 : S84 - S84
  • [2] The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations
    Samsudin, Firdaus
    Gan, Samuel Ken-En
    Bond, Peter J.
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2021, 19 (19): : 330 - 342
  • [3] Interference between Gag non-cleavage site mutation P453L and HIV-1 protease non-drug resistance mutation E35D
    Shibata, J.
    Ren, F.
    Nishizawa, M.
    Fujno, M.
    Iwatani, Y.
    Matsuda, M.
    Miura, H.
    Tanaka, H.
    Sugiura, W.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S143 - S143
  • [4] Interference between Gag non-cleavage site mutation P453L and HIV-1 protease non-drug resistance mutation E35D
    Shibata, J.
    Ren, F.
    Nishizawa, M.
    Fujno, M.
    Iwatani, Y.
    Matsuda, M.
    Miura, H.
    Tanaka, H.
    Sugiura, W.
    ANTIVIRAL THERAPY, 2007, 12 : S143 - S143
  • [5] Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1
    Myint, L
    Matsuda, M
    Matsuda, Z
    Yokomaku, Y
    Chiba, T
    Okano, A
    Yamada, K
    Sugiura, W
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) : 444 - 452
  • [6] Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors
    Aoki, Manabu
    Venzon, David J.
    Koh, Yasuhiro
    Aoki-Ogata, Hiromi
    Miyakawa, Toshikazu
    Yoshimura, Kazuhisa
    Maeda, Kenji
    Mitsuya, Hiroaki
    JOURNAL OF VIROLOGY, 2009, 83 (07) : 3059 - 3068
  • [7] Non-active site mutations play a major role in HIV-1 protease drug resistance
    Muzammil, S
    Ross, P
    Freire, E
    FASEB JOURNAL, 2003, 17 (05): : A1330 - A1330
  • [8] A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance
    Muzammil, S
    Ross, P
    Freire, E
    BIOCHEMISTRY, 2003, 42 (03) : 631 - 638
  • [9] Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 gag cleavage site in drug resistance and replication fitness
    Brann, Terrence W.
    Dewar, Robin L.
    Jiang, Min-Kan
    Shah, Akram
    Nagashima, Kunio
    Metcalf, Julia A.
    Falloon, Judith
    Lane, H. Clifford
    Imamichi, Tomozumi
    JOURNAL OF VIROLOGY, 2006, 80 (12) : 6136 - 6145